We like Boston Scientific, because they are a healthcare company and a specialist in stents. Nevertheless, today we have this: "Six physicians with financial ties to Johnson & Johnson and other heart-device makers will be advising U.S. regulators whether to restrict the use of some products because of potentially lethal side effects" and "The panel members, listed on an FDA Web site Nov. 22, will include Robert Harrington, who runs a Duke University research institute funded by stent makers J&J and Boston Scientific Corp".
We don't like this. To us, this is a bad practice. Let's see, what will say the markets today.
We don't like this. To us, this is a bad practice. Let's see, what will say the markets today.
No comments:
Post a Comment